Global diabetic kidney disease research from 2000 to 2017: A bibliometric analysis

Medicine (United States)

Volumn 98, Issue 6, 2019, Pages

  Zou, Lu Xi ^a   Sun, Ling ^b   Li, Yan ^c  

^a ZHEJIANG UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

^c NONE

Author keywords

bibliometric analysis; CiteSpace; diabetic kidney disease; VOSviewer

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; AUSTRALIA; AUTHOR; BIBLIOMETRICS; CANADA; CHINA; CITATION ANALYSIS; DIABETIC NEPHROPATHY; ENGLAND; GERMANY; HUMAN; INFLAMMATION; JAPAN; MEDICAL LITERATURE; MEDICAL RESEARCH; PODOCYTE; PRIORITY JOURNAL; PUBLICATION; QUANTITATIVE ANALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SOUTH KOREA; SPAIN; UNITED STATES; UNIVERSITY; STATISTICS AND NUMERICAL DATA; TRENDS;

BIBLIOMETRICS; BIOMEDICAL RESEARCH; DIABETIC NEPHROPATHIES; HUMANS; PUBLICATIONS;

EID: 85061248471     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000014394     Document Type: Article

References (40)

1. Atkins RC, Zimmet PZ. Int Soc N, Int Fed Kidney Fdn World Kidney D, Int Diabet F. Diabetic kidney disease: act now or pay later. Med J Aust 2010;192:272-4.
2. Persson F, Rossing P. Diagnosis of diabetic kidney disease: state of the art and future perspective. Kidney Int Suppl 2018;8:2-7.
3. Rocha NA, McCullough PA. Cardiovascular outcomes in diabetic kidney disease: insights from recent clinical trials. Kidney Int Suppl 2018;8:8-17.
4. Zhou H, Tan W, Qiu Z, et al. A bibliometric analysis in gene research of myocardial infarction from 2001 to 2015. Peer J 2018;6:e4354.
5. Liao HC, Tang M, Luo L, et al. A bibliometric analysis and visualization of medical big data research. Sustainability 2018;10:166.
6. van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics 2010;84:523-38.
7. Chen CM. CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inf Sci Technol 2006;57:359-77.
8. Wang L, Gao P, Zhang M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in china in 2013. JAMA 2017;317:2515-23.
9. Li MZ, Su L, Liang BY, et al. Trends in prevalence, awareness, treatment, and control of diabetesmellitus inmainland china from 1979 to 2012. Int J Endocrinol 2013;2013:753150.
10. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 1983;32(suppl 2):64-78.
11. Bermejo S, Pascual J, Soler MJ. The current role of renal biopsy in diabetic patients. Minerva Med 2018;109:116-25.
12. Hoshino J, Mise K, Ueno T, et al. A pathological scoring system to predict renal outcome in diabetic nephropathy. Am J Nephrol 2015;41:337-44.
13. Hoshino J, Furuichi K, Yamanouchi M, et al. A new pathological scoring system by the Japanese classification to predict renal outcome in diabetic nephropathy. PLoS One 2018;13:e0190923.
14. Cherney DZI, Bakris GL. Novel therapies for diabetic kidney disease. Kidney Int Suppl 2018;8:18-25.
15. Anders HJ, Davis JM, Thurau K. Nephron protection in diabetic kidney disease. N Engl J Med 2016;375:2096-8.
16. Agrawal V, Giri C, Solomon RJ. The effects of glucose-lowering therapies on diabetic kidney disease. Curr Diabetes Rev 2015;11:191-200.
17. Dekkers CCJ, Gansevoort RT, Heerspink HJL. New diabetes therapies and diabetic kidney disease progression: the role of SGLT-2 inhibitors. Curr Diab Rep 2018;18:27.
18. Sun L, Zou LX, Chen MJ. Make precision medicine work for chronic kidney disease. Med Princ Pract 2017;26:101-7.
19. Iyengar SK, Sedor JR, Freedman BI, et al. Genome-wide association and trans-ethnic meta-analysis for advanced diabetic kidney disease: family investigation of nephropathy and diabetes (FIND). PLoS Genet 2015;11: e1005352.
20. Argiles A, Siwy J, Duranton F, et al. CKD273, a new proteomics classifier assessing CKD and its prognosis. PLoS One 2013;8:e62837.
21. Siwy J, Schanstra JP, Argiles A, et al. Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. Nephrol Dial Transplant 2014;29:1563-70.
22. Yin ZY, Chen DY, Li BF. Global regulatory T-cell research from 2000 to 2015: a bibliometric analysis. PLoS One 2016;11:e0162099.
23. Boyack KW, Klavans R. Co-citation analysis, bibliographic coupling, and direct citation: which citation approach represents the research front most accurately? J Am Soc Inf Sci Technol 2010;61:2389-404.
24. Hu CP, Hu JM, Gao Y, et al. A journal co-citation analysis of library and information science in China. Scientometrics 2011;86:657-70.
25. Waltman L, van Eck NJ, Noyons ECM. A unified approach to mapping and clustering of bibliometric networks. J Informetr 2010;4:629-35.
26. Reyes-Gonzalez L, Gonzalez-Brambila CN, Veloso F. Using coauthorship and citation analysis to identify research groups: a new way to assess performance. Scientometrics 2016;108:1171-91.
27. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
28. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-46.
29. Parving HH, Lewis JB, Ravid M, et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006;69:2057-63.
30. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
31. Miao Y, Xu SY, Chen LS, et al. Trends of long noncoding RNA research from 2007 to 2016: a bibliometric analysis. Oncotarget 2017;8:83114-27.
32. De Cosmo S, Viazzi F, Piscitelli P, et al. Blood pressure status and the incidence of diabetic kidney disease in patients with hypertension and type 2 diabetes. J Hypertens 2016;34:2090-8.
33. Nikolsky E, Mehran R, Turcot D, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol 2004;94:300-5.
34. Yang ZJ, Liu J, Ge JP, et al. Prevalence of cardiovascular disease risk factor in the Chinese population: the 2007-2008 China National Diabetes and Metabolic Disorders Study. Eur Heart J 2012;33:213-20.
35. Hamada S, Gulliford MC. Multiple risk factor control, mortality and cardiovascular events in type 2 diabetes and chronic kidney disease: a population-based cohort study. BMJ Open 2018;8:e019950.
36. Winter L, Wong LA, Jerums G, et al. Use of readily accessible inflammatory markers to predict diabetic kidney disease. Front Endocrinol (Lausanne) 2018;9:225.
37. Futrakul N, Futrakul P. Biomarker for early renal microvascular and diabetic kidney diseases. Ren Fail 2017;39:505-11.
38. Jiang X, Zhang Q, Wang HB, et al. Associations of urinary, glomerular, and tubular markers with the development of diabetic kidney disease in type 2 diabetes patients. J Clin Lab Anal 2018;32:e22191.
39. Barr ELM, Barzi F, Hughes JT, et al. High baseline levels of tumor necrosis factor receptor 1 are associated with progression of kidney disease in indigenous australians with diabetes: the eGFR follow-up study. Diabetes Care 2018;41:739-47.
40. Coca SG, Nadkarni GN, Huang Y, et al. Plasma biomarkers and kidney function decline in early and established diabetic kidney disease. J Am Soc Nephrol 2017;28:2786-93.